RecruitingNCT06580106
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
A Prospective Pilot Study of the Genetic Determinants of Toxicity and Response to Azacitidine and Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia Through Evaluation of Polymorphisms in Pharmacokinetic Genes and Venetoclax Levels
Sponsor
Wake Forest University Health Sciences
Enrollment
50 participants
Start Date
Apr 9, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Written informed consent and HIPAA authorization for release of personal health information.
- Age ≥ 18 years of age at the time of enrollment
- Confirmed diagnosis of AML
- Planned initial treatment with azacitidine and venetoclax
- Ability to read and understand the English and/or Spanish language
- As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
Exclusion Criteria1
- None
Interventions
OTHERBiospecimen samples
Buccal swabs and Blood samples will be collected throughout study.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06580106
Related Trials
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222238 locations
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT066180019 locations
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT072164435 locations
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT066512299 locations
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
NCT064243401 location